Phase 2 Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given written consent before any study procedures begin
- People older than 10 years of age
- People with a good general health and activity level, rated 0 or 1 on a standard oncology performance scale (confirm with trial site)
- People expected to survive at least 12 weeks
- People who are not pregnant, and who are using appropriate contraception if there is any chance of becoming pregnant
- People whose cancer tests show signs of high-risk HPV infection
- People with Stage III or Stage IV cervical cancer, or cervical cancer that has come back after treatment
- People whose blood counts meet minimum levels — specifically, a neutrophil count of at least 1,000/mm³ and a platelet count of at least 100,000/mm³
- People whose kidney and liver function results fall within acceptable ranges on blood tests
- People who test negative for HIV and Hepatitis C virus (HCV)
Who may not be able to join:
- People with non-cancerous cervical conditions such as cervical polyps, cervical endometriosis, or certain benign cervical growths or tumours
- People with unexplained free air in the abdomen that is not related to a recent medical procedure
- People who have previously been treated with a specific type of antibody derived from mice called mouse SCC antibody
- People who have taken part in another clinical drug trial, or received an experimental drug, within the 28 days before the study start date
- People who have had a minor surgical procedure — including biopsy, needle aspiration, or insertion of a central venous line — within 2 days before the study start date
- People who are pregnant or currently breastfeeding
- People whose bone marrow function is too low, based on blood test results showing neutrophil count below 1,000/mm³, platelet count below 100,000/mm³, or haemoglobin below 9 g/dL
- People whose liver or kidney function falls outside acceptable ranges on blood tests, including those with significant protein in their urine (confirm with trial site)
- People with a serious active infection that requires intravenous (IV) antibiotics at the time of screening
- People who test positive for Hepatitis C, Hepatitis B, HIV, HTLV, syphilis, or tuberculosis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lung-Ji Chang, PhD, Shenzhen Geno-Immune Medical Institute
Phone: +86 0755-86573763
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety of CC-EIEs in patients using CTCAE version 4.0 standard to evaluate the level of adverse events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.